420 related articles for article (PubMed ID: 30842314)
21. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
25. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.
Bekar KW; Owen T; Dunn R; Ichikawa T; Wang W; Wang R; Barnard J; Brady S; Nevarez S; Goldman BI; Kehry M; Anolik JH
Arthritis Rheum; 2010 Aug; 62(8):2443-57. PubMed ID: 20506300
[TBL] [Abstract][Full Text] [Related]
26. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
27. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
Gorman C; Leandro M; Isenberg D
Lupus; 2004; 13(5):312-6. PubMed ID: 15230284
[TBL] [Abstract][Full Text] [Related]
28. CD19: a promising B cell target for rheumatoid arthritis.
Tedder TF
Nat Rev Rheumatol; 2009 Oct; 5(10):572-7. PubMed ID: 19798033
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
30. CAR T-Cell Therapy in Autoimmune Disease.
Merkt W; Lorenz HM; Schmitt M
N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
[No Abstract] [Full Text] [Related]
31. CAR T-Cell Therapy in Autoimmune Disease.
De Benedetti F; Diomedi Camassei F; Locatelli F
N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
[No Abstract] [Full Text] [Related]
32. CAR T-Cell Therapy in Autoimmune Disease.
Howard JF; Vu T; Mozaffar T
N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
[No Abstract] [Full Text] [Related]
33. B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit.
Soloviova K; Puliaeva I; Puliaiev M; Puliaev R; Via CS
Cell Immunol; 2020 Jul; 353():104117. PubMed ID: 32408197
[TBL] [Abstract][Full Text] [Related]
34. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
35. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
[TBL] [Abstract][Full Text] [Related]
36. CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.
Taubmann J; Müller F; Yalcin Mutlu M; Völkl S; Aigner M; Bozec A; Mackensen A; Grieshaber-Bouyer R; Schett G
Arthritis Rheumatol; 2024 Apr; 76(4):497-504. PubMed ID: 38114423
[TBL] [Abstract][Full Text] [Related]
37. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
Merino R; Iwamoto M; Fossati L; Izui S
J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
[TBL] [Abstract][Full Text] [Related]
38. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.
Wofsy D
J Immunol; 1986 Jun; 136(12):4554-60. PubMed ID: 3086436
[TBL] [Abstract][Full Text] [Related]
39. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
40. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
